← All trials
NCT04299724
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2020
- Primary completion
- Jul 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Mar 9, 2020
- Last posted
- Mar 9, 2020
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shenzhen Geno-Immune Medical InstituteLead sponsor
- China Medical UniversityCollaborator
- Shenzhen Geno-Immune Medical InstituteOverall official - principal investigator
- Shenzhen Geno-Immune Medical InstituteReponsible party - principal investigator
- Shenzhen Third People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.